Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer.
Michelakis ED, Webster L, Mackey JR. · 2008
Read Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. by Michelakis ED, Webster L, Mackey JR. (2008) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2567082.txt.
Description
Michelakis, Webster, and Mackey reviewed in 2008 the case for an old generic drug, dichloroacetate, as a metabolic treatment for cancer. Most solid tumours run an odd metabolism called the Warburg effect, burning sugar by glycolysis even when oxygen is plentiful. That switch is tied to tumours resisting apoptosis, the programmed cell death that normally culls faulty cells.
Dichloroacetate blocks an enzyme called pyruvate dehydrogenase kinase, pushing sugar fuel into the mitochondria, the cell's power stations, for full oxidation instead. In laboratory and animal studies this revived mitochondrial death signalling and suppressed tumour growth. The drug is taken by mouth and long used for other conditions. The authors lay out the scientific and clinical rationale for moving it quickly into early cancer trials.
Catalog record
| CREATOR | Michelakis ED, Webster L, Mackey JR. |
|---|---|
| YEAR | 2008 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |